Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29015317 | 1.00 | NR1H2 (0.43) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL1645992 | 1.00 | NR1H2 (0.43) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL15817337 | 1.00 | NR1H2 (0.43) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL1584537 | 1.00 | NR1H2 (0.43) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL16183221 | 0.88 | NR1H2 (0.41) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL1242322 | 0.88 | NR1H2 (0.41) | NR1H2SMN1; SMN2HSD17B10AGTR2CHRM2 | |
| SCHEMBL1914761 | 0.88 | NR1H2 (0.54) | NR1H2SMN1; SMN2HSD17B10CHRM2CHRM1 | |
| SCHEMBL3191040 | 0.88 | NR1H2 (0.54) | NR1H2SMN1; SMN2HSD17B10CHRM2CHRM1 | |
| SCHEMBL7807219 | 0.88 | NR1H2 (0.54) | NR1H2SMN1; SMN2HSD17B10CHRM2CHRM1 | |
| SCHEMBL26777581 | 0.88 | NR1H2 (0.54) | NR1H2SMN1; SMN2HSD17B10CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404030-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9738629-B2 | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-22 | — | — | US | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885SMN1; SMN2 816/4885HSD17B10 3620/4885 |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885SMN1; SMN2 816/4885HSD17B10 3620/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885SMN1; SMN2 816/4885HSD17B10 3620/4885 |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NR1H2 160/4885SMN1; SMN2 4737/4885HSD17B10 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.